A Randomized Trial Comparing Treatment Completion of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in HIV-negative Household Contacts of Recently Diagnosed Tuberculosis Patients, The â??One To Threeâ?? Trial - ONE TO THREE TRIA

The Aurum Institute NPC0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年1月9日

试验速览

暂无简介。

•Age >= 13 years
•Weight > 30 kg
•HIV-seropositive
•HIV viral load <400 copies/mL, defined as virally suppressed, on an efavirenz (EFV) or dolutegravir (DTG)-based ART regimen (see Section 3.6.2)
•Candidates must meet national criteria for receiving TPT

•Confirmed or suspected TB disease
•Likely to move from the study area during the study period
•Known recent exposure to a TB case with resistance to isoniazid or rifampicin
•Previous treatment for active or latent TB for more than 30 days within the past 2 years
•On nevirapine, etravirine, rilpivirine, PI-based, or raltegravir-containing ART regimens
•Known sensitivity or intolerance to isoniazid or rifamycins
•Suspected acute hepatitis or known chronic or unstable liver disease
•Alanine aminotransferase (ALT) > 3 times the upper limit of normal
•Total bilirubin > 2.5 times the ULN
•Pregnancy or breastfeeding Females of childbearing potential who are unable or unwilling to use two forms of contraception
•On prohibited medications

发起方

The Aurum Institute NPC